Company intelligence / Profile preview

Marius Pharmaceuticals

Raleigh, North Carolina, United Stateskyzatrex.com ↗

Ownership: Private
Development stage: Commercial

Overview

KYZATREX (testosterone undecanoate) CIII Capsules is an FDA-approved oral testosterone therapy for adult men with hypogonadism. The company recently achieved a significant milestone with the FDA removing the Black Box Warning from testosterone labels. They have completed Phase 3 studies for KYZATREX and have received FDA approval.

Therapeutic areas: Women's HealthEndocrinologyMen's Health
Modalities: Small molecules (oral testosterone therapy)
Industry: Biotech

Drug pipeline

1 asset

SOV-2012-F1

Unknown

Partnerships

Duke University School of MedicineUS Specialists Management LLC (USSM)Gameday Men's HealthThriveO2

Beyond the preview

Go deeper on Marius Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marius Pharmaceuticals.

Explore the full profile